JP2008519067A5 - - Google Patents

Download PDF

Info

Publication number
JP2008519067A5
JP2008519067A5 JP2007540251A JP2007540251A JP2008519067A5 JP 2008519067 A5 JP2008519067 A5 JP 2008519067A5 JP 2007540251 A JP2007540251 A JP 2007540251A JP 2007540251 A JP2007540251 A JP 2007540251A JP 2008519067 A5 JP2008519067 A5 JP 2008519067A5
Authority
JP
Japan
Prior art keywords
another example
studies
conducted
producing
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007540251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519067A (ja
JP5232472B2 (ja
Filing date
Publication date
Priority claimed from KR1020040089455A external-priority patent/KR101086254B1/ko
Application filed filed Critical
Publication of JP2008519067A publication Critical patent/JP2008519067A/ja
Publication of JP2008519067A5 publication Critical patent/JP2008519067A5/ja
Application granted granted Critical
Publication of JP5232472B2 publication Critical patent/JP5232472B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007540251A 2004-11-04 2005-11-03 向上された生体利用効率を備えるプランルカスト固体分散体組成物およびその固体分散体の製造方法 Expired - Fee Related JP5232472B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2004-0089455 2004-11-04
KR1020040089455A KR101086254B1 (ko) 2004-11-04 2004-11-04 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
PCT/KR2005/003686 WO2006049433A1 (en) 2004-11-04 2005-11-03 Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion

Publications (3)

Publication Number Publication Date
JP2008519067A JP2008519067A (ja) 2008-06-05
JP2008519067A5 true JP2008519067A5 (enExample) 2008-12-04
JP5232472B2 JP5232472B2 (ja) 2013-07-10

Family

ID=36319405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540251A Expired - Fee Related JP5232472B2 (ja) 2004-11-04 2005-11-03 向上された生体利用効率を備えるプランルカスト固体分散体組成物およびその固体分散体の製造方法

Country Status (6)

Country Link
JP (1) JP5232472B2 (enExample)
KR (1) KR101086254B1 (enExample)
AR (1) AR051758A1 (enExample)
MX (1) MX2007005427A (enExample)
TW (1) TWI380829B (enExample)
WO (1) WO2006049433A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101233235B1 (ko) * 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
EP2187968A4 (en) * 2007-08-21 2013-02-20 Univ Texas THERMOKINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS
EP4008314A3 (en) * 2007-08-21 2022-11-09 Board of Regents, The University of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
KR101381881B1 (ko) * 2012-03-12 2014-04-04 충남대학교산학협력단 용해도 및 용출율이 개선된 프란루카스트 나노 고체 분산체의 제조방법
KR101446129B1 (ko) * 2012-10-10 2014-10-06 조선대학교산학협력단 프란루카스트-함유 고형 제제의 제조방법
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
KR102363727B1 (ko) 2015-06-01 2022-02-16 삼아제약 주식회사 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법
WO2020012498A1 (en) 2018-07-13 2020-01-16 Council Of Scientific & Industrial Research Solid dispersion comprising an anticancer compound with improved solubility and efficacy
KR20240164596A (ko) 2023-05-09 2024-11-20 삼아제약 주식회사 복약편의성이 증진된 프란루카스트 함유 약제학적 조성물
KR102840220B1 (ko) 2023-07-18 2025-07-31 삼아제약 주식회사 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물
KR20250052834A (ko) 2023-10-12 2025-04-21 주식회사 다산제약 프란루카스트의 생체이용률이 개선된 약제학적 조성물 및 그 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
DE69625813T2 (de) * 1995-06-12 2003-09-04 Ono Pharmaceutical Co. Ltd., Osaka Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
US5858509A (en) * 1996-11-15 1999-01-12 Digital Equipment Corporation Attenuating vibrations in a mounting shelf for multiple disk drives
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Similar Documents

Publication Publication Date Title
JP2008519067A5 (enExample)
NL301202I1 (nl) Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
IL191711A0 (en) 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
JP2009544651A5 (enExample)
JP2007302683A5 (enExample)
HUS1400056I1 (hu) Glükopiranozil-helyettesített benzol-származékok, az említett vegyületeket tartalmazó gyógyszerek, azok alkalmazása, és eljárás elõállításukra
WO2005055976A3 (de) Pulver enthaltend niedermolekulares dextran und verfahren zu deren herstellung
PL1740156T3 (pl) Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej
SI1689370T2 (sl) Postopek za pripravo trdnega, oralno uporabnega farmacevtskega sestavka, ki obsega 5-klor-N(((5S)-2okso-3-(4-(3-okso-4-morfolinil)-fenil)-1,3-oksazolidin -5-il)-metil)-2-tiofenkarboksamid
JP2004161535A5 (enExample)
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
JP2009538861A5 (enExample)
WO2008130312A8 (en) A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701
JP2006339594A5 (enExample)
ATE531717T1 (de) Neue kristalline form eines pyridazinoä4,5- büindolderivats
IL180893A0 (en) Method for the preparation of a d-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative
SG170081A1 (en) Method of patterning and product(s) obtained therefrom
JP2006511228A5 (enExample)
WO2005121078A3 (de) Substituierte cyclopenten-verbindungen
TWI348593B (en) Amine compound, chemically amplified resist composition and patterning process
JP2008104450A5 (enExample)
WO2008065051A3 (de) Herstellung von festen lösungen von pestiziden durch kurzzeitüberhitzung und schnelle trocknung
IL190596A0 (en) 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
WO2008074693A3 (en) Process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone
IL187915A0 (en) 1,2-di(cyclic group)substituted benzene derivative